Stifel initiated coverage of Cogent Biosciences (COGT) with a Hold rating and $16 price target The firm says that while the shares could have some more upside into the Q4 readouts in gastrointestinal stromal tumors and advanced systemic mastocytosis, success of both studies is already priced into the stock. Cogent will soon face some profit taking given the over 100% rally since July and shorting into a “heavily debated” indolent systemic mastocytosis launch in the second half of 2026, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COGT:
- Cogent Biosciences added to Analyst Current Favorites list at Raymond James
- Cogent Biosciences Signs Lease for New Headquarters
- Optimistic Buy Rating for Cogent Biosciences Driven by Bezuclastinib’s Potential and Expected 68.2% Share Price Return
- Promising Market Potential for Cogent Biosciences’ Bezuclastinib in Systemic Mastocytosis Treatment
- Cogent Biosciences initiated with a Strong Buy at Raymond James